We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aprea Therapeutics Inc | NASDAQ:APRE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 1.76% | 4.05 | 3.73 | 4.16 | 4.10 | 3.92 | 3.92 | 1,953 | 00:11:33 |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Aprea Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
03836J102
(CUSIP Number)
HealthCap VII, L.P.
Represented by its general partner
HealthCap VII GP S.A.
23 Avenue Villamont
Lausanne, V8 CH -1005
+4121 614 3500
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
June 30, 2022
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No. 03836J102 Names of Reporting Persons. HealthCap VII, L.P. Check the Appropriate Box
if a Member of a Group (See Instructions) (a) ☐ (b) ☐ SEC Use Only Source of Funds (See
Instructions) WC Check if Disclosure of
Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐ Citizenship or Place of
Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With Sole Voting Power 0 Shared Voting Power 2,366,104 Sole Dispositive Power 0 Shared Dispositive Power 2,366,104 Aggregate Amount Beneficially Owned by Each Reporting Person 2,366,104 Check if the Aggregate
Amount in Row (11) Excludes Certain Shares (See Instructions) ☐ Percent of Class
Represented by Amount in Row (11) 10.1% Type of Reporting Person
(See Instructions) PN
CUSIP No. 03836J102 Names of Reporting Persons. HealthCap VII GP S.A. Check the Appropriate Box
if a Member of a Group (See Instructions) (a) ☐ (b) ☐ SEC Use Only Source of Funds (See
Instructions) AF Check if Disclosure of
Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐ Citizenship or Place of
Organization Switzerland Number of Shares Beneficially Owned by Each Reporting Person With Sole Voting Power 0 Shared Voting Power 2,366,104 Sole Dispositive Power 0 Shared Dispositive Power 2,366,104 Aggregate Amount Beneficially Owned by Each Reporting Person 2,366,104 Check if the Aggregate
Amount in Row (11) Excludes Certain Shares (See Instructions) ☐ Percent of Class
Represented by Amount in Row (11) 10.1% Type of Reporting Person
(See Instructions) OO
CUSIP No. 03836J102 Explanatory Note This Amendment No. 2 amends and supplements the Schedule 13D filed by the Reporting Persons on October 17, 2019, as amended by Amendment No. 1
thereto filed on October 15, 2021. Terms defined in the Schedule 13D are used herein as so defined. Interest in Securities of the Issuer Item 5 of the Schedule 13D is amended and supplemented as follows: (a)-(b) The information set forth in rows 7 through 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row
13 is based on 23,397,236 outstanding shares of Common Stock as reported in the Issuers definitive proxy statement on Schedule 14A, filed on June 10, 2022.
CUSIP No. 03836J102 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: June 30, 2022 HEALTHCAP VII L.P. By its general partner HealthCap VII GP SA By: /s/ Dag Richter Name: Dag Richter Title: Director By: /s/ Fabrice Bernhard Name: Fabrice Bernhard Title: General Manager HEALTHCAP VII GP SA
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
Item 5.
By:
/s/ Dag Richter
Name:
Dag Richter
Title:
Director
By:
/s/ Fabrice Bernhard
Name:
Fabrice Bernhard
Title:
General Manager
1 Year Aprea Therapeutics Chart |
1 Month Aprea Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions